Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Open Orphan Plc ( (GB:HVO) ) has shared an update.
hVIVO plc announced an update regarding its Non-Executive Director, Martin Gouldstone, who is also the CEO of Oncimmune Holdings plc. Oncimmune Holdings has been placed into administration as of March 26, 2025. This development may have implications for hVIVO’s governance and could impact stakeholders’ perceptions of the company’s stability and leadership.
More about Open Orphan Plc
hVIVO plc is a rapidly growing early-stage Contract Research Organisation (CRO) and the global leader in human challenge trials. The company provides comprehensive clinical development services to a diverse client base, including major biopharma companies. hVIVO operates a state-of-the-art quarantine facility in London and offers virology and immunology laboratory services. Through its subsidiaries, CRS and Venn Life Sciences, hVIVO offers early-phase clinical trial services and drug development consulting.
YTD Price Performance: -23.41%
Average Trading Volume: 3,109,103
Technical Sentiment Signal: Buy
Current Market Cap: £107.8M
For detailed information about HVO stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue